Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History LNTH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics LNTH

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Lantheus Holdings Inc

LNTH
Current price
80.81 USD +2.03 USD (+2.58%)
Last closed 79.19 USD
ISIN US5165441032
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 5 464 986 112 USD
Yield for 12 month +2.36 %
1Y
3Y
5Y
10Y
15Y
LNTH
21.11.2021 - 28.11.2021

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. Address: 201 Burlington Road, Bedford, MA, United States, 01730

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

129.31 USD

P/E ratio

22.50

Dividend Yield

Financials LNTH

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures LNTH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+1 533 910 000 USD

Last Year

+1 296 429 000 USD

Current Quarter

+372 764 000 USD

Last Quarter

+391 110 000 USD

Current Year

+988 291 000 USD

Last Year

+709 543 000 USD

Current Quarter

+237 700 000 USD

Last Quarter

+248 545 000 USD
EBITDA 510 356 000 USD
Operating Margin TTM 27.38 %
Price to Earnings 22.50
Return On Assets TTM 14.39 %
PEG Ratio 0.61
Return On Equity TTM 24.11 %
Wall Street Target Price 129.31 USD
Revenue TTM 1 536 699 008 USD
Book Value 16.84 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 0.80 %
Dividend Yield
Gross Profit TTM 984 145 024 USD
Earnings per share 3.51 USD
Diluted Eps TTM 3.51 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -45.50 %
Profit Margin 16.55 %

Stock Valuation LNTH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 22.50
Forward PE 11.52
Enterprise Value Revenue 3.35
Price Sales TTM 3.56
Enterprise Value EBITDA 11.72
Price Book MRQ 4.69

Technical indicators LNTH

For 52 weeks

73.11 USD 126.89 USD
50 Day MA 88.01 USD
Shares Short Prior Month 7 871 517
200 Day MA 94.77 USD
Short Ratio 5.47
Shares Short 7 992 068
Short Percent 15.20 %